Take this for what its worth as I own the company that makes Follidrone-
The first thing I would do is make a solid diet plan. I dont mean like atkins or whatever I mean a plan on exactly what you will eat, per day, per week for 8 weeks. PLan to adhere strictly to this plan. If you want to grow, aim for 500 above maintenance and increase when you plateau.
If you want to cut drop 500 and increase training volume and cardio.
No sugar. or extremely limited. If you have issues losing bodyfat sugar is the enemy not fats.
1.5+ grams of protein per lb of bodyweight.
I would run- Follidrone 2 caps pre workout 8 weeks. Works great for cutting and bulking. We have seen a ton of guys gain 4-11lbs
Many gaining a few even while in caloric deficit and losing bodyfat. (-)-epicatechin is great at assisting fat loss.
+
Formeron 4 pumps also 8 weeks.
(-)-Epicatechin: cardiometabolic clinical effects supported by preclinical model (829.2)
+ Author Affiliations
- [SUP]1[/SUP]Laboratorio de Investigacion Integral Cardiometabolica ESM-IPN Santo Tomas. Mexico City Mexico
- [SUP]2[/SUP]Department of Medicine UCSD La Jolla CA United States
Abstract
Background. Obesity associates with cardiometabolic disruptions. Lifestyle changes and pharmacologic therapies show moderately effective results. (-)-Epicatechin (EPI), the most abundant flavanol in cacao, has been associated with better cardiometabolic health.
Objective. To assess the effect of EPI in humans and explain findings through a preclinical study.
Methods. In humans, we performed a single-dose of EPI oral metabolic tolerance test and a 1-week trial, measuring cardiometabolic endpoints. In rats, we induced weight gain and cardiometabolic disruptions by a high-fat diet; afterwards, EPI was daily administered for 15 days. Weight gain, glycemia, arterial pressure, triglyceridemia, and HDL-cholesterol were measured; also, immonublot in skeletal muscle and adipose tissue were performed.
Results.
EPI enhanced lipid oxidation and attenuated hyperglycemia and hypertriglyceridemia during postprandial metabolism. EPI induced weight-loss, fat loss, and improved cardiometabolic endpoints in humans. In rats, EPI reduced weight gain, blood triglycerides, and hyperglycemia. EPI increased the expression of sirtuins, PCG-1α, mitofilin, UCP.
Conclusions.
EPI improved several cardiometabolic risk factors in both humans and animals by modulating energy metabolism. These findings make EPI an attractive candidate for human use in regards of treating obesity and its associated comorbidities.